Denali Capital Acquisition Corp. enters Amendment No. 2 to Merger Agreement with Semnur Pharmaceuticals

Semnur Pharmaceuticals, Inc.

Amendment No. 2 signed on July 22, 2025 modifies Exchange Ratio and Merger Consideration definitions.
Allows issuance of additional Semnur common shares pre-closing for private placement financing or advisor services.
Maintains the 1.25-to-1 exchange ratio between Denali and Semnur shares.
Parties include Denali Capital Acquisition Corp., Denali Merger Sub Inc., and Semnur Pharmaceuticals (Scilex subsidiary).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.